Table of Contents
Table of Contents
List of Tables
List of Figures
Merrion Pharmaceuticals Plc Snapshot
Merrion Pharmaceuticals Plc Overview
Key Information
Key Facts
Merrion Pharmaceuticals Plc - Research and Development Overview
Key Therapeutic Areas
Merrion Pharmaceuticals Plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Merrion Pharmaceuticals Plc - Pipeline Products Glance
Merrion Pharmaceuticals Plc - Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Merrion Pharmaceuticals Plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Merrion Pharmaceuticals Plc - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Merrion Pharmaceuticals Plc - Drug Profiles
alendronate sodium
Product Description
Mechanism of Action
R&D Progress
fondaparinux sodium
Product Description
Mechanism of Action
R&D Progress
MER-104
Product Description
Mechanism of Action
R&D Progress
zoledronic acid
Product Description
Mechanism of Action
R&D Progress
Merrion Pharmaceuticals Plc - Pipeline Analysis
Merrion Pharmaceuticals Plc - Pipeline Products by Therapeutic Class
Merrion Pharmaceuticals Plc - Pipeline Products by Route of Administration
Merrion Pharmaceuticals Plc - Pipeline Products By Mechanism of Action
Merrion Pharmaceuticals Plc - Recent Pipeline Updates
Merrion Pharmaceuticals Plc - Dormant Projects
Merrion Pharmaceuticals Plc - Locations And Subsidiaries
Head Office
Merrion Pharmaceuticals Plc, Recent Developments
Merrion Pharmaceuticals Plc- Press Release
Oct 09, 2009: Merrion Pharmaceuticals Plc Announce Presentation At ASCO, 2009 Breast Cancer Symposium, San Francisco.
Jun 11, 2009: Prostate Cancer - Positive Phase IIb Study For Orazol Tablet Form Of Zoledronate IV Infusion By Merrion Pharmaceuticals
Jun 01, 2009: Merrion Drug Orazol Could Be Used To Treat Breast Cancer
May 31, 2009: Merrion Announces Positive Final Results From Phase II Orazol Study
May 15, 2009: Merrion Pharmaceuticals Announces Preliminary Results From Phase II Orazol Study
Mar 10, 2009: Merrion Pharmaceuticals Announces Commencement Of Dosing of Orazol In US Clinical Study
Feb 10, 2009: Merrion Completes Patient Enrolment In Phase IIb Study - Results will Be Announced In Q2 2009
Feb 02, 2009: Merrion Pharmaceuticals Retains Sage Group to Augment Strategic Alliance Efforts
Financial Deals Landscape
Merrion Pharmaceuticals Plc, Deals Summary
Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Merrion Pharma Acquires A Pharma Facility For $5 Million
Venture Financing
Merrion Pharma Secures $10 Million In Venture Financing
Merrion Pharma Secures $7.54 Million In Venture Financing
Partnerships
Merrion Pharma Enters Into Research Agreement With Trinity College
Merrion Pharma Enters Into Research Agreement With Hunter-Fleming
Licensing Agreements
Merrion Pharma Enters Into Option Licensing Agreement With Novo Nordisk
Merrion Pharma Enters Into An Option Licensing Agreement With Rebel Pharma
Merrion Pharma Enters Into Licensing Agreement With Novo Nordisk For GLP-1
Merrion Pharma Enters Into Licensing Agreement With Novo Nordisk For Insulin Analogues
Equity Offering
Merrion Completes Private Placement Of $0.86 Million
Merrion Pharma Completes IPO Of $10.7 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Merrion Pharmaceuticals Plc, Key Information
Merrion Pharmaceuticals Plc, Key Facts
Merrion Pharmaceuticals Plc - Pipeline by Indication, 2012
Merrion Pharmaceuticals Plc - Pipeline by Stage of Development, 2012
Merrion Pharmaceuticals Plc - Monotherapy Products in Pipeline, 2012
Merrion Pharmaceuticals Plc - Phase III, 2012
Merrion Pharmaceuticals Plc - Phase II, 2012
Merrion Pharmaceuticals Plc - Phase I, 2012
Merrion Pharmaceuticals Plc - Pre-Clinical, 2012
Merrion Pharmaceuticals Plc - Pipeline By Therapeutic Class, 2012
Merrion Pharmaceuticals Plc - Pipeline By Route of Administration, 2012
Merrion Pharmaceuticals Plc - Pipeline Products By Mechanism of Action, 2012
Merrion Pharmaceuticals Plc - Recent Pipeline Updates, 2012
Merrion Pharmaceuticals Plc - Dormant Developmental Projects,2012
Merrion Pharmaceuticals Plc, Deals Summary
Merrion Pharma Acquires A Pharma Facility For $5 Million
Merrion Pharma Secures $10 Million In Venture Financing
Merrion Pharma Secures $7.54 Million In Venture Financing
Merrion Pharma Enters Into Research Agreement With Trinity College
Merrion Pharma Enters Into Research Agreement With Hunter-Fleming
Merrion Pharma Enters Into Option Licensing Agreement With Novo Nordisk
Merrion Pharma Enters Into An Option Licensing Agreement With Rebel Pharma
Merrion Pharma Enters Into Licensing Agreement With Novo Nordisk For GLP-1
Merrion Pharma Enters Into Licensing Agreement With Novo Nordisk For Insulin Analogues
Merrion Completes Private Placement Of $0.86 Million
Merrion Pharma Completes IPO Of $10.7 Million

List of Figures
Merrion Pharmaceuticals Plc - Pipeline by Indication, 2012
Merrion Pharmaceuticals Plc - Pipeline by Stage of Development, 2012
Merrion Pharmaceuticals Plc - Monotherapy Products in Pipeline, 2012
Merrion Pharmaceuticals Plc - Pipeline Products By Mechanism of Action, 2012

Click here to open the POPUP